SCHEMBL14633760

SCHEMBL14633760

CNc1nc(Nc2cc(C)cc(S(C)(=O)=O)c2)ncc1-c1n[nH]c2cc(F)c(F)cc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37
CDK9 P50750 2/20 0.37
JAK1 P23458 3/20 0.37
JAK3 P52333 2/20 0.37
LRRK2 Q5S007 5/20 0.36
PTGS2 P35354 1/20 0.36
SYK P43405 1/20 0.36
AURKA O14965 1/20 0.35
JAK2 O60674 1/20 0.35
EPHB4 P54760 1/20 0.35
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
MAP2K7 O14733 1/20 0.34
MAP2K4 P45985 1/20 0.34
CCNE2 O96020 1/20 0.34
CCNA2 P20248 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634045 0.95 JAK1 (0.38) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL14633508 0.95 JAK1 (0.38) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL2471137 0.89 CDK2 (0.36) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL2469164 0.89 RIPK2 (0.44) CDK2CDK9JAK1JAK3LRRK2
SCHEMBL2468102 0.89 CDK2 (0.39) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL14634249 0.88 CDK9 (0.40) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL2434666 0.86 PTGS2 (0.38) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL14634077 0.86 JAK1 (0.40) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL14633643 0.86 CDK2 (0.39) CCNT1CCNE1CDK2CDK9JAK1
SCHEMBL14633947 0.85 JAK1 (0.39) CDK2CDK9JAK1JAK3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CCNT1 331/4885CCNE1 340/4885CDK2 22/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CCNT1 282/4885CCNE1 203/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.